Christine Marie  Utter net worth and biography

Christine Utter Biography and Net Worth

Since joining PTC in 2010 as the assistant controller, Christine Utter has consistently taken on new responsibilities, growing to become senior vice president of finance and chief accounting officer in 2017. Previously, she was the assistant corporate controller of Barrier Therapeutics and a financial analyst at Engelhard Corporation. Christine holds a B.S. in accounting from the College of New Jersey and is a certified public accountant.

What is Christine Marie Utter's net worth?

The estimated net worth of Christine Marie Utter is at least $910,937.92 as of January 30th, 2024. Ms. Utter owns 35,528 shares of PTC Therapeutics stock worth more than $910,938 as of April 16th. This net worth evaluation does not reflect any other assets that Ms. Utter may own. Additionally, Ms. Utter receives an annual salary of $595,540.00 as CAO at PTC Therapeutics. Learn More about Christine Marie Utter's net worth.

How old is Christine Marie Utter?

Ms. Utter is currently 46 years old. There are 7 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Christine Marie Utter's age.

What is Christine Marie Utter's salary?

As the CAO of PTC Therapeutics, Inc., Ms. Utter earns $595,540.00 per year. There are 5 executives that earn more than Ms. Utter. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Christine Marie Utter's salary.

How do I contact Christine Marie Utter?

The corporate mailing address for Ms. Utter and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Christine Marie Utter's contact information.

Has Christine Marie Utter been buying or selling shares of PTC Therapeutics?

Christine Marie Utter has not been actively trading shares of PTC Therapeutics during the last ninety days. Most recently, Christine Marie Utter sold 318 shares of the business's stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $27.25, for a transaction totalling $8,665.50. Following the completion of the sale, the chief accounting officer now directly owns 35,528 shares of the company's stock, valued at $968,138. Learn More on Christine Marie Utter's trading history.

Who are PTC Therapeutics' active insiders?

PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Dawn Svoronos (Director), and Christine Utter (CAO). Learn More on PTC Therapeutics' active insiders.

Are insiders buying or selling shares of PTC Therapeutics?

During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 19 times. They sold a total of 149,295 shares worth more than $6,933,602.74. The most recent insider tranaction occured on April, 2nd when EVP Lee Scott Golden sold 526 shares worth more than $14,922.62. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.

Information on this page was last updated on 4/2/2024.

Christine Marie Utter Insider Trading History at PTC Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2024Sell318$27.25$8,665.5035,528View SEC Filing Icon  
1/8/2024Sell1,188$28.64$34,024.3237,499View SEC Filing Icon  
4/21/2023Sell4,692$55.06$258,341.5238,059View SEC Filing Icon  
3/29/2023Sell4,688$47.79$224,039.5238,059View SEC Filing Icon  
3/27/2023Sell26,658$45.09$1,202,009.2238,059View SEC Filing Icon  
1/31/2023Sell325$45.63$14,829.7538,059View SEC Filing Icon  
1/11/2023Sell417$44.36$18,498.1238,384View SEC Filing Icon  
1/9/2023Sell706$41.66$29,411.9639,290View SEC Filing Icon  
2/1/2022Sell313$40.00$12,520.00View SEC Filing Icon  
1/18/2022Sell11,428$43.94$502,146.32View SEC Filing Icon  
1/7/2022Sell747$38.52$28,774.44View SEC Filing Icon  
2/1/2021Sell368$56.96$20,961.2817,161View SEC Filing Icon  
2/1/2021Sell368$56.96$20,961.2817,161View SEC Filing Icon  
1/5/2021Sell316$62.37$19,708.92View SEC Filing Icon  
11/4/2020Sell31,758$60.06$1,907,385.4811,129View SEC Filing Icon  
10/6/2020Sell2,500$50.08$125,200.0010,349View SEC Filing Icon  
7/6/2020Sell3,288$53.70$176,565.60View SEC Filing Icon  
4/17/2020Sell2,145$50.00$107,250.0011,449View SEC Filing Icon  
4/3/2020Sell787$44.31$34,871.9710,091View SEC Filing Icon  
1/7/2020Sell13,750$50.02$687,775.005,224View SEC Filing Icon  
7/1/2019Sell14,059$45.14$634,623.265,173View SEC Filing Icon  
6/28/2019Sell988$45.00$44,460.005,173View SEC Filing Icon  
3/5/2019Sell28,709$34.97$1,003,953.735,937View SEC Filing Icon  
1/7/2019Sell297$34.75$10,320.75View SEC Filing Icon  
1/4/2018Sell412$17.67$7,280.04View SEC Filing Icon  
See Full Table

Christine Marie Utter Buying and Selling Activity at PTC Therapeutics

This chart shows Christine Marie Utter's buying and selling at PTC Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PTC Therapeutics Company Overview

PTC Therapeutics logo
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Read More

Today's Range

Now: $25.29
Low: $25.15
High: $26.32

50 Day Range

MA: $28.12
Low: $24.15
High: $31.95

2 Week Range

Now: $25.29
Low: $17.53
High: $59.84


712,695 shs

Average Volume

940,367 shs

Market Capitalization

$1.94 billion

P/E Ratio


Dividend Yield